VTAK

8-K - Catheter Precision, Inc. (0001716621) (Filer)

FORT MILL, S.C., April 21, 2026 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE:VTAK) today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for key claims covering its proprietary surgical vessel closing pressure device, marking a significant milestone in the Company's intellectual property strategy. Following a rigorous examination process, the USPTO confirmed the novelty and patentability of VTAK's technology over existing prior art. The allowed claims provide protection across both the core device architecture and its method of use, creating a comprehensive and defensible intellectual property position around a foundational compo

Major Carriers Accelerate Route Cuts as Economics Break Down, Creating Multi-Billion-Dollar Opportunity in Regional Air Mobility Flyte Expands Focus on High-Frequency Short-Haul Routes to Capture Surging Demand as Industry Economics Continue to Shift FORT MILL, S.C., April 20, 2026 (GLOBE NEWSWIRE) -- Flyte, the regional air mobility subsidiary of Catheter Precision, Inc. (NYSE:VTAK), today announced it is accelerating expansion in short-haul markets as major global airlines rapidly retreat from regional routes amid rising fuel costs, operational constraints, and shifting route economics. This pullback reflects a structural shift, creating a sustained opportunity for high-frequency regio

Transaction Delivers Fully Consolidated, Revenue-Generating, Aviation Business with Accelerating Growth Positions VTAK for Scalable Expansion in Regional Air Mobility Ahead of eVTOL Commercialization FORT MILL, S.C., April 16, 2026 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE:VTAK) today announced it received shareholder approval on April 15th of the definitive agreement to acquire Fly Flyte, Inc. ("Flyte") executed on March 9. The March 9th transaction establishes Flyte as a wholly owned operating subsidiary, delivering immediate consolidation of revenue, assets, and operating performance into VTAK. Full Ownership, Consolidated Revenue and Immediate Operating Exposure Flyte ope

8-K - Catheter Precision, Inc. (0001716621) (Filer)

FORT MILL, S.C., April 13, 2026 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE:VTAK) ("VTAK" or the "Company") today announced that the results of a recently concluded VIVO study have been accepted in EP Europace, the leading European electrophysiology journal. The EP Europace journal provides an avenue of communication for top-quality European and international original, scientific work and reviews in the fields of arrhythmias, pacing and cellular electrophysiology. The journal offers readers a collection of contemporary, original, peer-reviewed papers, invited papers and editorial comments, together with book reviews and correspondence. The accepted manuscript titled "Accuracy of a

FORT MILL, S.C., April 08, 2026 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE:VTAK) ("VTAK" or the "Company") today announced that it will be attending the annual European Heart Rhythm Association (EHRA) conference in Paris, France from April 12-14, 2026. EHRA is one of several conferences supported by the European Society of Cardiology whose mission is to reduce the number of people with cardiovascular diseases by connecting cardiovascular health professionals around the world to disseminate the latest knowledge, innovations and guidelines. As a community, they work together to empower healthcare providers to transform cardiovascular care from a privilege to a universal right. Davi

FORT MILL, S.C., April 06, 2026 (GLOBE NEWSWIRE) --  Catheter Precision, Inc. (NYSE:VTAK) ("VTAK" or the "Company") today announced that the manuscript titled "Safety and Efficacy of LockeT Suture Retention Device for Large-Bore Venous Access Closure" has been accepted by the Journal of Interventional Cardiac Electrophysiology (JICE), a leading medical journal in the field of electrophysiology. This publication confirmed the safety and efficacy of LockeT for large-bore venous closure in 139 patients and concluded that LockeT demonstrated high procedural success, rapid hemostasis, early ambulation, and low complication rates for venous closure following EP procedures requiring LBVA. These

8-K - Catheter Precision, Inc. (0001716621) (Filer)

10-K - Catheter Precision, Inc. (0001716621) (Filer)

Clinical, Commercial and Regulatory Milestones Achieved in 2025 Establish a Strong Foundation in Life Sciences as Revenue Increases 95% Year Over Year Acquisition of Flyte and Strengthened Capital Position Unlock Multi-Segment Growth Strategy with Multiple Near-Term Catalysts FORT MILL, S.C., March 31, 2026 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE:VTAK) ("VTAK" or the "Company"), a U.S.-based innovative medical device company focused on electrophysiology products, today announced its financial results and operational update for the fourth quarter and full year ended December 31, 2025 as well as certain other business updates. 2025: Execution Across Clin

4 - Catheter Precision, Inc. (0001716621) (Issuer)

4 - Catheter Precision, Inc. (0001716621) (Issuer)

4 - Catheter Precision, Inc. (0001716621) (Issuer)

4 - Catheter Precision, Inc. (0001716621) (Issuer)

4 - Catheter Precision, Inc. (0001716621) (Issuer)

Hops Scalable Vision Jet Fleet Expansion Unlocking High-Frequency Short-Haul Regional Travel Flyte's Vision Jet-Powered Hops Platform Aims to Establish a New Standard in Regional Travel with Industry-Leading Safety, Speed, Efficiency and Affordability FORT MILL, S.C., March 25, 2026 (GLOBE NEWSWIRE) --  Catheter Precision, Inc. (NYSE:VTAK) and its wholly-owned subsidiary Fly Flyte, Inc. ("Flyte"), today announced the expansion of its Vision Jet-powered Hops platform, a scalable short-haul regional travel solution designed to deliver faster, safer, and more affordable private aviation than competitors. Flyte currently operates three aircraft, with two additional Vision Jets under accepted

DEFA14A - Catheter Precision, Inc. (0001716621) (Filer)

DEF 14A - Catheter Precision, Inc. (0001716621) (Filer)

Fleet Expansion Underway With Five Vision Jets Expected to Be Operating by Memorial Day Regional Aviation Platform Now Connects Entire East Coast Following Successful Soft Launch in Florida FORT MILL, S.C., March 16, 2026 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE:VTAK) today announced the official launch of Flyte Hops Florida, expanding Flyte's regional aviation network from its original New York-based service to now providing multiple aircraft along the entire East Coast from Maine to Florida. As previously announced, Flyte is a wholly-owned subsidiary of the company. The launch follows a recent soft operational rollout in Florida, which occurred while one of Flyte's Cirrus Vi

PRE 14A - Catheter Precision, Inc. (0001716621) (Filer)

FORT MILL, S.C., March 11, 2026 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE:VTAK) today announced transformational balance sheet improvements through new institutional capital commitments supporting the Company's next phase of growth. Fully Funded Growth StrategyFly Flyte, Inc. ("Flyte"), a newly acquired subsidiary of VTAK, is now positioned to execute its expansion strategy with a fully funded growth plan supported by its parent company, Catheter Precision. VTAK has recently completed multiple strategic financings designed to support the Company's transformation and the expansion of the Flyte aviation platform. The financing also provides capital to fund the Company's medical d

Transaction Delivers Wholly Owned, Scalable Asset-Backed, Aviation Platform with Accelerating Revenue and Consolidated Control Positions VTAK at the Center of High-Growth Regional Air Mobility Ahead of Industry-Wide eVTOL CommercializationFORT MILL, S.C., March 10, 2026 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE:VTAK) today announced that it has completed the acquisition of the remaining 80.02% equity interest in Fly Flyte, Inc. ("Flyte") from Creatd, Inc. (OTCQB:CRTDD), resulting in 100% ownership of the AI-enabled regional aviation operator. The transaction converts Flyte from a minority strategic investment into a wholly owned operating subsidiary, establishing VTAK as the ow

NEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- Creatd, Inc. (OTCQB:CRTDD) today announced that it has sold its remaining 80% equity stake in its subsidiary, Fly Flyte, Inc. ("Flyte"), to Catheter Precision, Inc. (NYSE:VTAK). Under the terms of the completed transaction, Creatd will receive approximately $6,000,000 in cash and nearly $6,000,000 in Convertible Preferred Stock of VTAK. The NYSE-approved transaction considerably strengthens Creatd's balance sheet. The sale is consistent with Creatd's strategy of developing turnkey operating solutions that prepare businesses for listing on the public markets while simultaneously retaining a minority interest in them. The transaction positions Cr

8-K - Catheter Precision, Inc. (0001716621) (Filer)